Chemical Compound
Butanedioic acid, 2-hydroxy-, (2S)-, compd. with N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1); Cabozantinib S-malate; Cabozantinib s-malate; Cometriq; XL 184; Cabozantinib L-malate salt; Cabozantinib (S)-malate
CAS Registry Number
1140909-48-3
Primary record
Butanedioic acid, 2-hydroxy-, (2S)-, compd. with N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1); Cabozantinib S-malate; Cabozantinib s-malate; Cometriq; XL 184; Cabozantinib L-malate salt; Cabozantinib (S)-malate
- 库存
- 7,558 克
- 纯度
- 99.6 %
- CAS
- 1140909-48-3
化合物标识与属性
- CAS
- 1140909-48-3
- PubChem CID
- 25102846
- SMILES
- COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C([C@@H](C(=O)O)O)C(=O)O
- Canonical SMILES
- COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC.O=C(O)C[C@H](O)C(=O)O
名称与同义词
- Cabozantinib S-malate
- Cabozantinib malate
- cabozantinib (S)-malate
- Cabometyx
- 1140909-48-3
- Cometriq
- Cabozantinib malate (XL184)
- Cabozantinib (S-malate)
- cabozantinib L-malate
- Cabometyx (TN)
- Cometriq (TN)
- RESNIBEN
- XL184
- Cabozantinib L-Malate Salt
- XL-184 malate
- Cabozantinib S-malate?
- Cabozantinib s-malate [USAN]
- DR7ST46X58
- UNII-DR7ST46X58
- RefChem:1080604
- XL 184
- XL-184
- Cabozantinib malate (JAN)
- Cabozantinib S-Malate salt
- MFCD20923480
- XL184(Cabozantinib malate)
- CHEBI:72319
- MLS006010951
- C32H30FN3O10
- Cabozantinib s-malate (USAN)
- DTXSID60915949
- BMS907351
- orb1307421
- BMS 907351
- CHEMBL2103868
- SCHEMBL29350740
- SCHEMBL29881226
- CABOZANTINIB MALATE [JAN]
- HFCFMRYTXDINDK-WNQIDUERSA-N
- DTXCID501510465
- GLXC-10543
- BMS-907351
- C28H24FN3O5.C4H6O5
- EX-A2819
- KS-00000LA2
- 2296AH
- EBC-17171
- s4001
- 1140909-48-3 (malate)
- 1140909-48-3 (malate salt)
- AKOS025401945
- CABOZANTINIB S-MALATE [WHO-DD]
- CCG-270301
- CS-0201
- FC64967
- AC-27471
- AS-75255
- HY-12044
- SC-91041
- SMR004702755
- SY105860
- 9-(4-chlorophenyl)sulfonylnon-6-en-2-one
- CABOZANTINIB S-MALATE [ORANGE BOOK]
- Cyclobutanol, 2-(phenylsulfonyl)-, trans-
- (2,6-diphenylphenyl) 2-methylprop-2-enoate
- B1401
- SW218093-2
- C10465
- D10095
- W-5841
- Butanedioic acid, 2-hydroxy-, (2S)-, compd. with N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1)
- XL184 (S-malate);BMS-907351 (S-malate)
- A856828
- (2S)-2-Hydroxybutanedioic acid compd. with N-[4-[(
- Q27139901
- trimethyl-(7-methyl-1,4-dihydronaphthalen-1-yl)silane
- B2693-457054
- (2S)-2-Hydroxybutanedioic acid compd. with N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1)
- 1-N-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-1-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;(2S)-2-hydroxybutanedioic acid
- N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (S)-2-hydroxysuccinate
- Cabozantinib malate, 98%, a potent VEGFR2 inhibitor - 10MG 10mg
- (2S)-2-Hydroxybutanedioic acid compd. with N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluor
- (2s)-2-hydroxybutanedioic acid compd. with n-(4-((6,7-dimethoxy-4-quinolinyl)oxy)phenyl)-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1)
- (2S)-2-Hydroxybutanedioic acid compd. with N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide
- (2S)-2-Hydroxybutanedioic acid compd. with N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1)
- (2S)-2-Hydroxybutanedioic acid--N~1~-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'~1~-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (1/1)
- (2S)-2-hydroxybutanedioic acid; N'1-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
- 1,1-Cyclopropanedicarboxamide, N'-(4-((6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4- fluorophenyl)- mono((2S)-2-hydroxybutanedioate)
- 114091-64-4
- 114092-06-7
- 114092-82-9
- 114093-21-9
- 849217-68-1
- BUTANEDIOIC ACID, 2-HYDROXY-, (2S)-, COMPD. WITH N-(4-((6,7-DIMETHOXY-4-QUINOLINYL)OXY)PHENYL)-N'-(4-FLUOROPHENYL)-1,1-CYCLOPROPANEDICARBOXAMIDE (1:1)
- Butanedioic acid, 2-hydroxy-, (2S)-, compd. with N-[4-[(6,7- dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1,1- cyclopropanedicarboxamide
- Butanedioic acid, 2-hydroxy-, (2S)-, compd. with N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1); Cabozantinib S-malate; Cabozantinib s-malate; Cometriq; XL 184; Cabozantinib L-malate salt; Cabozantinib (S)-malate
- cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinoline-4-yloxy)-phenyl]-amide(4-fluoro-phenyl)-amide, (S) malate salt
- inverted exclamation mark N-[4-[(6,7-Dimethoxyquinolin-4-yl)oxy]phenyl]-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (S)-2-Hydroxysuccinate
- N'-[4-[(6,7-DIMETHOXY-4-QUINOLINYL)OXY]PHENYL]-N-(4-FLUOROPHENYL)-1,1-CYCLOPROPANEDICARBOXAMIDE
- N-(4-((6,7-DIMETHOXYQUINOLIN-4-YL)OXY)PHENYL)-N'-(4-FLUOROPHENYL)CYCLOPROPANE-1,1-DICARBOXAMIDE MONO((2S)-2-HYDROXYBUTANEDIOATE)
- N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (S)-2-hydroxysuccinate
- N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (2S)-2-Hydroxybutanedioic Acid
- N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (2S)-2-hydroxybutanedioate
- N1-[4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-N1'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;(2S)-2-hydroxybutanedioic acid